Related Experiment Video
Updated: Feb 6, 2026

Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease
Published on: March 24, 2023
Rifaximin in nonalcoholic fatty liver disease: hit multiple targets with a single shot
Ahmed Abdel-Razik1, Nasser Mousa1, Walaa Shabana1
1Departments of Tropical Medicine.
Background/Aims:
The pathogenesis of nonalcoholic fatty liver disease (NAFLD) may include increased insulin resistance, upregulation of proinflammatory cytokines, lipopolysaccharide, and BMI. Rifaximin is a minimally absorbable antibiotic that might act against a broad spectrum of gut bacteria. This study aimed to investigate the effects of rifaximin on NAFLD.
Patients And Methods:
Fifty participants with biopsy-proven nonalcoholic steatohepatitis (NASH) were registered in this multicentric, double-blind, randomized, placebo-controlled study. BMI, alanine aminotransferase, aspartate aminotransferase, γ-glutamyl transferase, lipid profile, serum endotoxin, homeostatic model assessment, toll-like receptor-4, interleukin-10 (IL-10), IL-6, tumor necrosis factor-α, and cytokeratin-18 (CK-18) levels were evaluated at baseline and at 1, 3, and 6 months of rifaximin therapy (1100 mg/day).
Results:
Patients were randomized into two groups (rifaximin group; n=25 and placebo group; n=25). After 6 months of rifaximin therapy, patients with NASH showed a significant reduction in homeostatic model assessment, alanine aminotransferase, aspartate aminotransferase, γ-glutamyl transferase, endotoxin, toll-like receptor-4, IL-6, tumor necrosis factor-α, CK-18, and NAFLD-liver fat score (all P<0.05), but no changes in the lipid profile; moreover, there was a mild nonstatistically significant reduction of BMI. However, in the placebo group, there was no significant difference in these variables at baseline and after therapy.
Conclusion:
Rifaximin therapy appears to be effective and safe in modifying NASH through reduction of serum endotoxin and improvement of insulin resistance, proinflammatory cytokines, CK-18, and NAFLD-liver fat score.
Insights
Rifaximin significantly improved nonalcoholic steatohepatitis (NASH) by reducing endotoxin and inflammation markers. This antibiotic therapy offers a safe approach to managing NASH, improving insulin resistance and liver fat score.
Area of Science:
- Hepatology
- Gastroenterology
- Pharmacology
Background:
- Nonalcoholic fatty liver disease (NAFLD) pathogenesis involves insulin resistance, inflammation, and gut-derived endotoxins.
- Rifaximin, a poorly absorbed antibiotic, targets gut bacteria and may influence NAFLD progression.
Purpose of the Study:
- To investigate the efficacy and safety of rifaximin in treating nonalcoholic steatohepatitis (NASH).
Main Methods:
- A multicentric, double-blind, randomized, placebo-controlled study involving 50 patients with biopsy-proven NASH.
- Evaluated biomarkers including liver enzymes, lipid profile, endotoxin, insulin resistance (HOMA), inflammatory cytokines (TLR-4, IL-6, TNF-α), and cytokeratin-18 (CK-18) over 6 months.
Main Results:
- Rifaximin therapy led to significant reductions in HOMA, liver enzymes, endotoxin, TLR-4, IL-6, TNF-α, and CK-18 (P<0.05).
- No significant changes were observed in lipid profiles or BMI.
- The placebo group showed no significant improvements in these parameters.
Conclusions:
- Rifaximin therapy is effective and safe for modifying NASH.
- It reduces serum endotoxin, improves insulin resistance, and decreases inflammatory markers and liver fat.
- Rifaximin shows promise in managing NASH patients.
More Related Videos
09:27Analysis of Liver Microenvironment During Early Progression of Non-Alcoholic Fatty Liver Disease-Associated Hepatocellular Carcinoma in Zebrafish
Published on: April 1, 2021
11:08The Use of Gas Chromatography to Analyze Compositional Changes of Fatty Acids in Rat Liver Tissue during Pregnancy
Published on: March 13, 2014
Related Concept Videos
Diseases of the Liver and Gallbladder
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Bioavailability Study Design: Single Versus Multiple Dose Studies
Multiple Allele Traits
Overview of Fatty Acid Metabolism
Fatty acids are catabolized in a process called beta-oxidation, which takes place in the matrix of the mitochondria and converts their fatty acid chains into two-carbon units of acetyl groups. The acetyl...
Multiple Regression
Farmers can use multiple regression to determine the crop yield based on more than one factor, such as water availability, fertilizer, soil properties, etc. Here, the crop yield is the response or dependent variable as it depends on the other independent variables. The analysis requires the construction of a scatter plot...